MedPath

To assess the changes in vessels of the eye after using magnesium sulphate in pregnant females with hypertension due to pregnancy

Not Applicable
Conditions
Health Condition 1: O141- Severe pre-eclampsia
Registration Number
CTRI/2020/05/025083
Lead Sponsor
Post Graduate Institute of Medical Education and Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

severely pre eclamptic women, 30-38 weeks of gestation who are scheduled to receive MgSO4

Exclusion Criteria

Women with chronic hypertension, eclampsia, chronic renal disease, hyperthyroidism, twin gestation, seizure disorder, noninsulin dependent diabetes mellitus, severe anemia, autoimmune disorders and those with ocular injuries or prior ocular surgery

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The change in peak ratio after magnesium sulphate administration at 60 minsTimepoint: The change in peak ratio after magnesium sulphate administration at 60 mins
Secondary Outcome Measures
NameTimeMethod
1. The baseline ophthalmic artery indices (resistive index, pulsatility index and peak ratio) in severely pre eclamptic women <br/ ><br>2. The change in resistive index after magnesium sulphate administration <br/ ><br>3. The change in pulsalitiy index after magnesium sulphate administration <br/ ><br>Timepoint: 0mins, 60 mins and 24 hours
© Copyright 2025. All Rights Reserved by MedPath